Share Name Share Symbol Market Type Share ISIN Share Description
Smith & Nephew Plc LSE:SN. London Ordinary Share GB0009223206 ORD USD0.20
  Price Change % Change Share Price Shares Traded Last Trade
  -18.50 -1.62% 1,121.50 2,319,094 13:56:20
Bid Price Offer Price High Price Low Price Open Price
1,121.00 1,122.00 1,151.50 1,120.50 1,147.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 3,854.13 433.33 44.22 22.7 9,868
Last Trade Time Trade Type Trade Size Trade Price Currency
13:58:09 O 8 1,121.924 GBX

Smith & Nephew (SN.) Latest News

More Smith & Nephew News
Smith & Nephew Investors    Smith & Nephew Takeover Rumours
Smart Money!
SN. is a large holding in the following funds:
 Fund  Percentage of Fund  Last Updated 

Smith & Nephew (SN.) Discussions and Chat

Smith & Nephew Forums and Chat

Date Time Title Posts
16/6/202211:42*** Smith and Nephew ***543
10/1/201113:03Smith and Nephew 200867
09/1/201117:12Smiths: Charts and News etc.296
25/9/200615:09Smith&Nep. Why the rise?75

Add a New Thread

Smith & Nephew (SN.) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Smith & Nephew trades in real-time

Smith & Nephew (SN.) Top Chat Posts

Smith & Nephew Daily Update: Smith & Nephew Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker SN.. The last closing price for Smith & Nephew was 1,140p.
Smith & Nephew Plc has a 4 week average price of 1,108p and a 12 week average price of 1,108p.
The 1 year high share price is 1,598.50p while the 1 year low share price is currently 1,108p.
There are currently 879,866,271 shares in issue and the average daily traded volume is 2,146,447 shares. The market capitalisation of Smith & Nephew Plc is £9,867,700,229.27.
pdosullivan: I doubled my holding in this one earlier today. It makes no sense for SN/ to be trading 2% above the COVID trough when electives were cancelled etc.
chamer1: With a trading update imminent on Thursday and much to be positive about with this company I think you will be lucky to see the low 12s again, unless the general market is very poor for the first part of the week and SN. tracks it down unavoidably. I think now is time to stay invested and we could see £18 by the end of 2022
its the oxman: You would think so. Mkt not very forward looking for SN but very happy to price in returning demand for airlines and the like. Not sure what we are missing here.
gclark: I don't agree with the general business comments above, but I do see the supply issues and cancelled elective surgeries as the major stumbling blocks, but these should be transient. I invest in stocks for the future prospects, and am probably a bit overweight here, but I see that enormous investment will go into clearing the backlog of surgeries that SN products are used in, and I believe they will get their market share of those surgeries so will hold. You always wonder what the reasons are behind large share sales, and maybe there is a particular reason we don't know. AIMHO
trekker60: "Such a frustrating share" Ain't it just! Bought in here a year before Covid appeared and am still sitting on a loss. But after such a long wait, I'm reluctant to sell out now so am reconciled to this 'investment' being dead money for a while yet until, hopefully, the company's fortubes benefit more significantly from global healthcare trends. Or there's a bid approach - but that has periodically been rumpoured for years and nothing has materalised so not holding my breath on that one. Yep, 'frustrating' is the word!
roguetraderuk: underweight here. execution isnt there and india news yet to be put into mix. due to update 22nd feb. im interested in adding at 10ish and 7ish if seen. i expect the jnj arm once spun off will be in for these in a couple of years. stryker in the states has executed far better could be interested but there could be comp issues. medtronic will also report on 22nd feb, also having its own execution issues and on similar 22 pe of about 18. stryker, the better business is on 25 times. this year (22) should be better (less covid) and 23 far better (even less covid?) but its all about how they execute individually. back to sn. im underweight until they can turn the corner or price drops lower enough but a bidder to surface. we arent there yet on either front.
suetballs: Like the backlog of cases the rise in the share price is delayed!!! Such a frustrating share. Suet
luzley: C/o Adastra LSE ASC's are the real key for S&N to outperform25 Jan 2022 12:18 The light at the end of the Covid19 tunnel is now clearly visible and the engagement of Spire by the govt to assist the NHS in attacking the elective surgery backlog is heartening in the UK. I have my sights firmly set on the progress being made across the pond in the ASC (ambulatory surgical centres). The company is firing on all cylinders to capture market share here as a prime mover. The last acquisition and RNS on Jan 19th was music to my ears as is today's very useful director appointment. S&N are focussing on ASC's as they are lucrative, high-margin avenues in which S&N has firmly embedded itself. If you look at the range of indicators here it is exceptional - sports injury, repair and cemented/cementless knee replacement with SOTA robotics, the company is bang on the money. Add in the huge Malaysian facility due to open this year to service the far East and the recently announced Baltic region hub and you start to see the bigger picture.
1nf3rn0: Analysts at Berenberg raised their target price on medical services firm Smith & Nephew from £18.25 to £18.40 on Friday following the firm's "extensive meet-the-management event" a day earlier.Berenberg stated Smith & Nephew had laid out its medium-term margin expectations and committed to regular share buybacks at the event, leading it to take a fresh look at the stock in order to factor the new disclosure into its forecasts.Overall, Berenberg said its view on S&N remained unchanged, asserting that it was "a much better business" than the market gives it credit for and, if it can deliver on its promises, the analysts said potential upside for the shares was "significant".Factoring in recent Covid-19 trends and new guidance resulted in 7-9% reductions to the German bank's 2022-2026 adjusted earning per share estimates but Berenberg stated a slight drop in the risk-free rate and a lower equity weighting in its weighted average cost of capital calculation, along with rolling the discounted cash flow forward to 2022, meant its DCF-derived price target increased to £18.40 per share, almost exactly 50% above Thursday's closing priceWhile Berenberg, which reiterated its 'buy' rating on the stock, acknowledged that Smith & Nephew's products were largely used in elective surgery procedures, leaving it "vulnerable" to the effects of Covid-19 on procedure rates, the analysts believe the however long effects from the coronavirus persist, it expects them to be "transitory" and to have "little to no bearing on the long-term outlook".
roguetraderuk: some advice re sn. the share price will begin to outperform when the mkt believes elected surgery for sn. has turned the corner. it will likely go mkt perform as others start giving signals (stryker, medtronic, intuitive etc) but as i say the big outperformance will come when the company points to a return to trend growth. demand issue and supply chains issues all due to covid and the variants are extending the point of turn in trend. i think it should reach equilibrium by q2 2022, i suspect the shares will bottom by then if not sooner. it all depends on the news and if its leaked and other news from others in the area. i dont think they will get too much cheaper as i would expect the americans to start sniffing. there is plenty to put right at sn. but that means a large upside for any buyer. personally i think they will stay independant until jnj do their split and the jnj arm likely picks up sn. but we will see. if they get cheap enough (10 quid or lower) someone may step up earlier. given that they are likely to underperfrom their peers next year, i wouldnt expect outperformance from here now, but of course i cant see the future and a bid would change all that.
Smith & Nephew share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Smith & Ne..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220705 13:13:52